Loading
Paris haematologist who led AZA-AML-001, the trial that showed azacitidine can extend survival for older people with acute myeloid leukaemia who cannot have intensive chemotherapy.
Hervé Dombret is a haematologist at Hôpital Saint-Louis in Paris and a long-standing leader of the French ALFA and GRAALL leukaemia cooperative groups. He was first author of the 2015 Blood report of AZA-AML-001, the international phase 3 trial of azacitidine against conventional care regimens in older patients with newly diagnosed AML and more than 30 percent marrow blasts, which supported azacitidine's use in this population.
Shares Acute myeloid leukaemia and the tags leukaemia, trialist.
Shares Acute myeloid leukaemia and the tags leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts, Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.